Clinical implications of the 5α-androstanedione pathway for castration-resistant prostate cancer

Future Oncology

Volumn 7, Issue 11, 2011, Pages 1239-1241

  Sharifi, Nima ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

5 androstanedione; abiraterone acetate; androgen receptor; dihydrotestosterone; prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANEDIOL; ANDROSTANEDIONE; ANDROSTANOLONE; STEROID 5ALPHA REDUCTASE; TESTOSTERONE;

CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; ENZYME ACTIVITY; ENZYME INHIBITION; HORMONE ACTION; HORMONE METABOLISM; HUMAN; ISOMERIZATION; OXIDATION; PRIORITY JOURNAL; RECEPTOR BINDING; REDUCTION; REVIEW; STEROIDOGENESIS; TESTOSTERONE SYNTHESIS;

3-HYDROXYSTEROID DEHYDROGENASES; ANDROSTADIENES; ANDROSTENEDIOL; ANTINEOPLASTIC AGENTS; DEHYDROEPIANDROSTERONE; ETIOCHOLANOLONE; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TESTOSTERONE;

EID: 80455125996     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.98     Document Type: Review

References (20)

1. De Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364(21), 1995-2005 (2011).
2. Sharifi N, Gulley JL, Dahut WL. An update on androgen deprivation therapy for prostate cancer. Endocr. Relat. Cancer 17(4), R305-R315 (2010).
3. Mostaghel EA, Page ST, Lin DW et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 67(10), 5033-5041 (2007). (Pubitemid 46910214)
4. Geller J, Albert J, Loza D, Geller S, Stoeltzing W, de la Vega D. DHT concentrations in human prostate cancer tissue. J. Clin. Endocrinol. Metab. 46(3), 440-444 (1978). (Pubitemid 8305058)
5. Montgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68(11), 4447-4454 (2008).
6. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin. Cancer Res. 11(13), 4653-4657 (2005). (Pubitemid 41557182)
7. Sharifi N, McPhaul MJ, Auchus RJ. "Getting from here to there" - mechanisms and limitations to the activation of the androgen receptor in castration-resistant prostate cancer. J. Investig. Med. 58(8), 938-944 (2010).
8. Deslypere JP, Young M, Wilson JD, McPhaul MJ. Testosterone and 5α dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol. Cell. Endocrinol. 88(1-3), 15-22 (1992).
9. Bruchovsky N, Wilson JD. The intranuclear binding of testosterone and 5α androstan 17b ol 3 one by rat prostate. J. Biol. Chem. 243(22), 5953-5960 (1968).
10. Locke JA, Guns ES, Lubik AA et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 68(15), 6407-6415 (2008).
11. Lorence MC, Murry BA, Trant JM, Mason JI. Human 3β-hydroxysteroid dehydrogenase/D5→4isomerase from placenta: expression in nonsteroidogenic cells of a protein that catalyzes the dehydrogenation/ isomerization of C21 and C19 steroids. Endocrinology 126(5), 2493-2498 (1990). (Pubitemid 20173038)
12. Simard J, Ricketts ML, Gingras S, Soucy P, Feltus FA, Melner MH. Molecular biology of the 3β-hydroxysteroid dehydrogenase/d5 d4 isomerase gene family. Endocr. Rev. 26(4), 525-582 (2005). (Pubitemid 41014265)
13. Evaul K, Li R, Papari-Zareei M, Auchus RJ, Sharifi N. 3β-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. Endocrinology 151(8), 3514-3520 (2010).
14. Stanbrough M, Bubley GJ, Ross K et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66(5), 2815-2825 (2006).
15. Russell DW, Wilson JD. Steroid 5α reductase: two genes/two enzymes. Annu. Rev. Biochem. 63, 25-61 (1994).
16. Chang KH, Li R, Papari-Zareei M et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc. Natl Acad. Sci. USA 108(33), 13728-13733 (2011).
17. Attard G, Reid AH, A'Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27(23), 3742-3748 (2009).
18. Efstathiou E, Tu S, Aparicio A et al. Use of "intracrine androgen signaling signature" to predict benefit from abiraterone acetate (AA) in patients with castrate-resistant prostate cancer (CRPC).Presented at: 2010 ASCO Annual Meeting. Chicago, IL, USA June 2010
19. Shah SK, Trump DL, Sartor O, Tan W, Wilding GE, Mohler JL. Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J. Urol. 181(2), 621-626 (2009).
20. Sharifi N. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer. Expert Opin Investig. Drugs 19(7), 837-846 (2010).